Maxele Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Maxele Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$904K	Buy	+4,755	New	+$817K	0.63%	45
2025 Q4	$785K	Sell	4,652 -18	-0.4%	-$2.92K	0.64%	44
2025 Q3	$674K	Hold	4,670	–	–	0.58%	47
2025 Q2	$591K	Sell	4,670 -10	-0.2%	-$1.23K	0.52%	49
2025 Q1	$599K	Sell	4,680 -143	-3%	-$19.4K	0.58%	47
2024 Q4	$638K	Buy	+4,823	New	+$678K	0.61%	48
2022 Q3	$492K	Sell	4,207 -50	-1%	-$6.21K	0.83%	38
2022 Q2	$501K	Sell	4,257 -245	-5%	-$29.1K	0.79%	38
2022 Q1	$587K	Sell	4,502 -543	-11%	-$70.7K	0.73%	41
2021 Q4	$770K	Buy	+5,045	New	+$781K	0.89%	36

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Maxele Advisors's IBB Position: Q2 2026 in Review

Maxele Advisors opened a new position in iShares Biotechnology ETF (IBB) in Q2 2026: 4,755 shares worth $904K. The stake represents 0.63% of the portfolio and ranks #45 among its holdings. This is a return to the name: Maxele Advisors previously reported a position in IBB as recently as Q4 2025.

Maxele Advisors first reported a position in IBB in Q4 2021 and has held it in 10 quarters since. 955 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Maxele Advisors held 4,755 shares of iShares Biotechnology ETF worth $904K as of Q2 2026.
iShares Biotechnology ETF was a new Maxele Advisors position in Q2 2026.
iShares Biotechnology ETF made up 0.63% of Maxele Advisors's portfolio in Q2 2026, its #45 holding.
Maxele Advisors first reported a position in iShares Biotechnology ETF in Q4 2021 and has held it in 10 quarters since.
955 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Maxele Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.